140 related articles for article (PubMed ID: 9368023)
1. Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2.
Bourgeois L; Brillard-Bourdet M; Deperthes D; Juliano MA; Juliano L; Tremblay RR; Dubé JY; Gauthier F
J Biol Chem; 1997 Nov; 272(47):29590-5. PubMed ID: 9368023
[TBL] [Abstract][Full Text] [Related]
2. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.
Charlesworth MC; Young CY; Miller VM; Tindall DJ
J Androl; 1999; 20(2):220-9. PubMed ID: 10232657
[TBL] [Abstract][Full Text] [Related]
3. Kininogen-derived fluorogenic substrates for investigating the vasoactive properties of rat tissue kallikreins--identification of a T-kinin-releasing rat kallikrein.
El Moujahed A; Brillard-Bourdet M; Juliano MA; Moreau T; Chagas JR; Gutman N; Prado ES; Gauthier F
Eur J Biochem; 1997 Jul; 247(2):652-8. PubMed ID: 9266709
[TBL] [Abstract][Full Text] [Related]
4. Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none.
Deperthes D; Marceau F; Frenette G; Lazure C; Tremblay RR; Dubé JY
Biochim Biophys Acta; 1997 Nov; 1343(1):102-6. PubMed ID: 9428664
[TBL] [Abstract][Full Text] [Related]
5. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors.
Lövgren J; Airas K; Lilja H
Eur J Biochem; 1999 Jun; 262(3):781-9. PubMed ID: 10411640
[TBL] [Abstract][Full Text] [Related]
6. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors.
Mikolajczyk SD; Millar LS; Kumar A; Saedi MS
Prostate; 1998 Jan; 34(1):44-50. PubMed ID: 9428387
[TBL] [Abstract][Full Text] [Related]
7. Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids.
Pimenta DC; Chao J; Chao L; Juliano MA; Juliano L
Biochem J; 1999 Apr; 339 ( Pt 2)(Pt 2):473-9. PubMed ID: 10191281
[TBL] [Abstract][Full Text] [Related]
8. Specificity of S'1 and S'2 subsites of human tissue kallikrein using the reactive-centre loop of kallistatin: the importance of P'1 and P'2 positions in design of inhibitors.
Pimenta DC; Fogaça SE; Melo RL; Juliano L; Juliano MA
Biochem J; 2003 May; 371(Pt 3):1021-5. PubMed ID: 12578561
[TBL] [Abstract][Full Text] [Related]
9. Differences in substrate and inhibitor sequence specificity of human, mouse and rat tissue kallikreins.
Fogaça SE; Melo RL; Pimenta DC; Hosoi K; Juliano L; Juliano MA
Biochem J; 2004 Jun; 380(Pt 3):775-81. PubMed ID: 15040788
[TBL] [Abstract][Full Text] [Related]
10. A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein.
Chen VC; Chao L; Chao J
J Biol Chem; 2000 Dec; 275(51):40371-7. PubMed ID: 10991942
[TBL] [Abstract][Full Text] [Related]
11. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence.
Zhou GX; Chao L; Chao J
J Biol Chem; 1992 Dec; 267(36):25873-80. PubMed ID: 1334488
[TBL] [Abstract][Full Text] [Related]
12. Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1.
Finlay JA; Day JR; Rittenhouse HG
Urology; 1999 Apr; 53(4):746-51. PubMed ID: 10197850
[TBL] [Abstract][Full Text] [Related]
13. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.
Lövgren J; Rajakoski K; Karp M; Lundwall â ; Lilja H
Biochem Biophys Res Commun; 1997 Sep; 238(2):549-55. PubMed ID: 9299549
[TBL] [Abstract][Full Text] [Related]
14. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation.
Deperthes D; Frenette G; Brillard-Bourdet M; Bourgeois L; Gauthier F; Tremblay RR; Dubé JY
J Androl; 1996; 17(6):659-65. PubMed ID: 9016396
[TBL] [Abstract][Full Text] [Related]
15. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein.
Chen VC; Chao L; Chao J
J Biol Chem; 2000 Dec; 275(49):38457-66. PubMed ID: 10993887
[TBL] [Abstract][Full Text] [Related]
16. S(1)' and S(2)' subsite specificities of human plasma kallikrein and tissue kallikrein 1 for the hydrolysis of peptides derived from the bradykinin domain of human kininogen.
Lima AR; Alves FM; Angelo PF; Andrade D; Blaber SI; Blaber M; Juliano L; Juliano MA
Biol Chem; 2008 Dec; 389(12):1487-94. PubMed ID: 18844446
[TBL] [Abstract][Full Text] [Related]
17. Comparison of human and porcine tissue kallikrein substrate specificities.
Del Nery E; Chagas JR; Juliano MA; Juliano L; Prado ES
Immunopharmacology; 1999 Dec; 45(1-3):151-7. PubMed ID: 10615005
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Kallikrein-Related Peptidases 7 and 5 by Grafting Serpin Reactive-Center Loop Sequences onto Sunflower Trypsin Inhibitor-1 (SFTI-1).
Jendrny C; Beck-Sickinger AG
Chembiochem; 2016 Apr; 17(8):719-26. PubMed ID: 26574674
[TBL] [Abstract][Full Text] [Related]
19. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2.
Mikolajczyk SD; Millar LS; Marker KM; Grauer LS; Goel A; Cass MM; Kumar A; Saedi MS
Eur J Biochem; 1997 Jun; 246(2):440-6. PubMed ID: 9208936
[TBL] [Abstract][Full Text] [Related]
20. Substrate specificities of tissue kallikrein and T-kininogenase: their possible role in kininogen processing.
Chagas JR; Hirata IY; Juliano MA; Xiong W; Wang C; Chao J; Juliano L; Prado ES
Biochemistry; 1992 Jun; 31(21):4969-74. PubMed ID: 1599922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
